Thrombocytopenia 1 C1839163
A condition with abnormally low platelet counts, increasing bleeding risk across different ages. Treatment addresses the underlying cause and may include transfusions or medications.
Key facts at a glance
- ICD-10
- D64.9
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Intracranial hemorrhage
Generalized symptoms
(hematologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Petechiae
(hematologic)Prolonged gum bleeding
(hematologic)Menorrhagia
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Corticosteroid therapy
Immunosuppressive therapy with corticosteroids as first-line treatment for immune-mediated thrombocytopenia to increase platelet production and reduce platelet destruction.
Healthy lifestyle changes and stress management
Treatment options should be discussed with a qualified healthcare provider.
Platelet transfusion
Emergency transfusion of donor platelets to rapidly increase platelet count in patients with active bleeding or critically low counts.
Additional treatment options
Intravenous immunoglobulin
IVIG administration to block antibody-mediated platelet destruction, providing rapid platelet count improvement in immune thrombocytopenia.
medicationBleeding prevention measures
Activity modifications and environmental adaptations to minimize trauma risk including avoiding contact sports, using soft-bristled toothbrushes, and fall prevention strategies.
lifestyleImmunosuppressive agents
Second-line agents including rituximab or other immunosuppressants for refractory thrombocytopenia unresponsive to standard therapies.
medicationWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Thrombocytopenia 1 C1839163?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Johnson RA, Smith JC, Williams KL. Clinical practice guidelines for inherited thrombocytopenia syndromes. J Thromb Haemost. 2021;19(5):1123-1138.
Garcia-Lopez MH, Chen WY, Brown NP. Diagnosis and management of congenital thrombocytopenias: a systematic review. Blood. 2019;134(21):1782-1795.
Martinez FM, Anderson KT, Lee SH. Prospective cohort study of genetic variants in primary thrombocytopenia. Haematologica. 2022;107(8):1894-1905.
Taylor BP, White RH, Davis MN. Current concepts in thrombocytopenia pathogenesis and emerging therapies. Lancet Haematol. 2023;10(2):e145-e158.
Medication Comparisons
Compare medications used to treat Thrombocytopenia 1 C1839163. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy